Subscribe to NRx Newsletter

Pipeline

PSYCHIATRY

Indication
Preclinical
Phase 1
Phase 2
Phase 3

BIPOLAR DEPRESSION & SUICIDAL IDEATION

Severe Bipolar Depression with Recently Suicidal Patients post stabilization

NRX-100™ / NRX-101™

Phase 3
FDA SPA, Breakthrough Therapy, Biomarker letter of Support – Integrating with P2b/3
Treatment of Suicidal Treatment-Resistant Bipolar Depression

NRX-101™

Phase 3
Currently Enrolling, Phase 2b/3 – Data Readout Expected Q4 2023
Expanded Access / Safety Study

NRX-101™

Preclinical
300+ Expected by Q2 2024

POST TRAUMATIC STRESS DISORDER (PTSD) WITH DEPRESSION & SUICIDALITY

PTSD in patients with Depression & Suicidality

NRX-101™

Enrollment Pending
Enrollment Pending – Data Readout Expected in 2023

CHRONIC PAIN WITH DEPRESSION

Depression in Patients with Chronic Pain

NRX-101™

Planning
Planning – Data Readout Expected in 2024

Expanded Access Policy on RTT: NRX-101 is not currently available outside of clinical trials.